To the Editor: Pulmonary Langerhans cell histiocytosis (PLCH) in adults is a rare disease occurring almost exclusively in smokers. The characteristic high-resolution computed tomography (HRCT) manifestation of PLCH is a combination of cysts (or cavities) and nodules mainly in the upper lung zone.\[[@ref1]\] However, not all HRCT patterns of PLCH are typical. Few treatments are effective in current practice regarding PLCH. Targeted therapy with an inhibitor of mutated *BRAF* (vemurafenib) has been proved effective in Langerhans cell histiocytosis (LCH) harboring *BRAF* valine at position 600 (V600E) mutation.\[[@ref2]\] *MAP2K1* mutations are mutually exclusive with *BRAF* mutations and might have implications for the use of BRAF targeted therapy.\[[@ref3]\] Here, we reported a case of PLCH proven by lung biopsy.

A 61-year-old man was referred to our institution for evaluation of intermittent cough with white phlegm. He had been a former smoker (cumulative dose = 20 pack/years) and quit approximately one year before. A chest HRCT scan \[[Figure 1a](#F1){ref-type="fig"}\] revealed, besides emphysema, diffuse nodules up to 1.5 cm in diameter spread in both lung fields without associated lymphadenopathy or pleural effusions. Positron emission tomography-computed tomography (CT) showed diffuse nodules in lung, many of which revealed increased ^18^F-deoxyglucose uptake (the average standardized uptake value \[SUV\]: 2.3; maximum SUV: 3.0). Pulmonary function test revealed moderate mixed restriction and obstruction pattern. Routine laboratory tests, ultrasound cardiogram, and bronchoscopy were unremarkable. CT-guided percutaneous transthoracic fine-needle aspiration (FNA) of pulmonary lesions was performed twice, showing atypical epithelial cells. The patient was discharged upon his own request.

![(a) Chest high-resolution computed tomography findings of the patient. (b) Histopathological findings of the lung biopsy specimen. H and E stain showed cellular nodule with aggregates of Langerhans cells (original magnification ×200); immunohistochemistry for CD1a and S100 demonstrated positive staining in Langerhans cells (original magnification ×200). (c) Sequencing of *MAP2K1* and *BRAF*. One silent mutation (code "CAG" to "CAA" at position 610) in exon 2 of *MAP2K1* was detected while no mutations in exon 3 of *MAP2K1* or in exon 15 of *BRAF* were detected.](CMJ-129-1384-g001){#F1}

Two months later, reexamined chest HRCT \[[Figure 1a](#F1){ref-type="fig"}\] showed a marked increase in the number and size of nodules, with diameter up to 2.0 cm. The patient underwent video-assisted thoracoscopic surgical (VATS) biopsy of the left upper and lower lobes. During the procedure, many palpable nodules were noted in lung parenchyma with diameters ranging from 0.3 to 1.8 cm. A key morphological feature of LCH cells on microscopic examination was noted, which was their highly convoluted nuclear membranes, and the cells strongly expressed Cluster of Differentiation (CD)1a and S100 \[[Figure 1b](#F1){ref-type="fig"}\]. PLCH diagnosis was made. Treatment started with prednisone (PDN) (0.5 mg·kg^−1^·d^−1^ for 1 month). Unfortunately, chest HRCT obtained one month later showed an increase in the number and size of nodular lesions \[[Figure 1a](#F1){ref-type="fig"}\]. Based on the results of LCH-III,\[[@ref4]\] a randomized international clinical trial embarked by the Histiocyte Society, an adjusted chemotherapeutic regimen of methotrexate (MTX) + vindesine (VDS) + PDN was pursued, i.e., MTX 500 mg/m^2^ once every two weeks intravenous (i.v.), VDS 3 mg/m^2^ once a week i.v., PDN 30 mg/m^2^ d1-30 orally (afterward weekly reduction). He experienced WHO Grade 1/2 toxicities including hepatotoxicity, nausea, and vomiting. One month later, chest HRCT showed a partial clearing of nodules \[[Figure 1a](#F1){ref-type="fig"}\], and his cough resolved. To explore whether the patient would benefit from the BRAF inhibitor therapy, *BRAF* and *MAP2K1* mutations were further tested. Deoxyribonucleic acid (DNA) was extracted from formalin-fixed and paraffin-embedded (FFPE) samples of the surgical biopsy after histological detection of histiocyte-rich areas, using QIAmp DNA FFPE tissue kit (QIAGEN, Germany) according to instructions. Exon 2 and exon 3 of *MAP2K1* and exon 15 of *BRAF* were amplified by polymerase chain reaction and sequenced with primers as listed in [Table 1](#T1){ref-type="table"}. As indicated in [Figure 1c](#F1){ref-type="fig"}, one silent mutation (code "CAG" to "CAA" at position 610) in exon 2 of *MAP2K1* was detected. However, there were no mutations in exon 3 of *MAP2K1* and exon 15 of *BRAF*. The experiment was approved by the Ethics Committee of Drum Tower Hospital, and the patient gave written informed consent.

###### 

Polymerase chain reaction and sequencing primers for *MAP2K1* (exon 2 and exon 3) and *BRAF* (exon 15)

  Template          Sequence (5'-3')            Product size (bp)
  ----------------- --------------------------- -------------------
  *MAP2K1* exon 2                               530
   Forward          CTCTCTAGCCTCCCACTTTGATT     
   Reverse          GTTTGAACCCAGGAGATGGA        
  *MAP2K1* exon 3                               356
   Forward          CCTTCCTCCCTCTTTCTTTCATA     
   Reverse          CCCAAGCTCTACAGTTAGACTTCC    
  *BRAF* exon 15                                587
   Forward          TACTATCTGCAGCATCTTCATTCC    
   Reverse          TACTATAGTTGAGACCTTCAATGAC   

Several findings of this case were quite unique and rare. First, the chest HRCT manifestation of this patient was diffuse nodules alone throughout the lung, without formation of cysts or cavities. Second, the onset of disease was nearly one year after smoking cessation. Diffuse lung nodules progressed both in number and size despite smoking cessation. Third, corticosteroid monotherapy failed to control disease progression while intensified combination chemotherapy (MTX + VDS + PDN) showed efficacy. Finally, and particularly, *BRAF* and *MAP2K1* of the lung lesions were sequenced. One *MAP2K1* mutation was observed while *BRAF* V600E mutation was not detected. To the best of our knowledge, the report regarding *MAP2K1* mutations in single-system PLCH was seldom and a new mutation site was identified (code "CAG" to "CAA" at position 610 in exon 2 of *MAP2K1*). These findings differentiate this case from the usual case of PLCH seen in clinical practice.

PLCH usually has little systemic damage. In this case, we did not find extrapulmonary disease manifestations. In elder patients with pure nodular forms in chest HRCT, it is especially important to exclude malignancy, which is why this patient received twice CT-guided percutaneous transthoracic FNA followed by VATS lung biopsy. It is generally thought that lung bases are spared in PLCH. However, in this patient, nodules extended into the lower lung zones and costophrenic angles were infiltrated, which might associate with the severity of disease.

Persisting uncertainty about the pathogenesis of PLCH has limited current treatment alternatives. Smoking cessation has been regarded as a treatment; however, worsening conditions despite cessation was observed in this case, indicating that PLCH might be induced by antigens in cigarette smoke but not terminated by smoke cessation. The role of smoking cessation on disease progress seems indifferent. In this case, corticosteroid monotherapy failed to control the disease. This patient further received chemotherapy (MTX + VDS + PDN) according to LCH-III.\[[@ref4]\] HRCT imaging showed improvement one month later. Even though this case is one-system LCH, involving the lung might associate with rapid progression and worse prognosis, thus a more intensive chemotherapeutic regimen might be necessary as in multisystem LCH. The most common activating somatic mutation in *BRAF* gene is a substitution of glutamic acid for V600E, which has been identified in a part of LCH cases. This mutation results in constitutive activation of the mitogen-activated protein kinase (MAPK) pathway. *MAP2K1* encodes the dual-specificity kinase of the MAPK pathway. *MAP2K1* mutations have been demonstrated to confer resistance to BRAF inhibitor therapy in LCH and other neoplasms.\[[@ref5]\] A mutation in exon 2 of *MAP2K1* was positive in this patient. Even though it is a silent mutation, it indicates there might be another mechanism of MAPK pathway activation in *BRAF* V600E-negative PLCH. There is clearly a necessity for better therapies for PLCH.
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